Navigation Links
Enobia Announces Positive Clinical Results With ENB-0040, a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia
Date:9/14/2009

DENVER, Sept. 14 /PRNewswire/ -- Enobia Pharma today announced positive data from a clinical study of ENB-0040, a bone targeted enzyme replacement therapy, under investigation for the treatment of hypophosphatasia (HPP). After six months of treatment with ENB-0040, four of five severely affected patients showed marked improvements in bone mineralization, correction of skeletal defects, better respiratory function, including weaning from assisted ventilation, and cognitive and motor development. These findings were presented by Dr. Michael Whyte at the 31(st) Annual Meeting of the American Society for Bone and Mineral Research in Denver, CO.

HPP is a genetic disease characterized primarily by defective bone mineralization and is caused by a deficiency in the enzyme tissue non-specific alkaline phosphatase (TNSALP). This enzyme plays a key role in regulating skeletal mineralization. There are currently no therapies approved for HPP. As an enzyme replacement therapy designed to specifically target TNSALP to the bones, ENB-0040 may help correct the enzyme deficiency and restore bone mineralization.

"Poor bone formation in infants with severe hypophosphatasia has devastating consequences, including fractures, respiratory failure and death in approximately half the infants," stated Michael P. Whyte, M.D., Medical/Scientific Director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospitals for Children in St. Louis and an investigator for the study. "The findings from this study are very encouraging, as they demonstrate correction of the primary skeletal disturbance after treatment with ENB-0040."

"The results from this study in infants and young children mark an important milestone for our program," said Hal Landy, M.D., Chief Medical Officer and Vice President, Medical Affairs of Enobia. "We are pleased that all five patients who completed the s
'/>"/>

SOURCE Enobia Pharma Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
2. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
3. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
4. Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia
5. Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial
6. Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
7. Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
8. Tobira Therapeutics Inc. Announces In Vitro Data of TBR-652 for the Treatment of HIV
9. Exsulin Corporation Announces Next Phase II Trial of Novel Islet Regeneration Treatment in Type 1 Diabetes
10. ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
11. BHR Pharma Announces Phase 3 SyNAPSe Study of Progesterone as a Neuroprotective Agent for Traumatic Brain Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BOSTON , Sept. 16, 2014 QPID ... a move to new headquarters in Boston ... The new headquarters will be at 175 Franklin Street in ... operations and marketing teams. QPID Health,s new Southern ... Parkway in Carlsbad.  The expansion will help meet the demands ...
(Date:9/16/2014)... , Sept. 16, 2014  Decision Resources Group finds that the ... billion in 2013 to over $18.2 billion in 2023 in ... Germany , Italy , ... and Japan . TNF-alpha inhibitors will remain the ... RA market, but growth will be constrained and patient shares will ...
(Date:9/16/2014)... 2014  Formex, LLC ("Formex"), a leader in ... Weilersbacher joined Formex as Director of Quality ... Greg Weilersbacher has over 20 ... in Quality Assurance, Facility Validation, GMP manufacturing, and ... to Formex a diverse wealth of experience. ...
Breaking Medicine Technology:QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
(Date:9/16/2014)... September 16, 2014 Who:, The Pulmonary ... Medical Campus and Children’s Hospital Colorado are ... the country’s leading pulmonary hypertension association that works to find ... disease of the lungs that affects the functioning of the ... mean survivability is only 2.8 years. , What:, Colorado ...
(Date:9/16/2014)... September 16, 2014 As part of ... Latin American Citizens (LULAC) will host the second annual ... Salud will feature free health screenings for osteoporosis, HIV, ... includes glucose and cholesterol levels as well as bone ... for children under 6 years old , The event ...
(Date:9/16/2014)... 16, 2014 (HealthDay News) -- Including women older than ... to a sharp reduction in advanced forms of the ... breast cancer screening programs could result in older women ... So, the decision to screen older women for breast ... recommended. "Instead of using mass screening, the decision ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. ... cancer survivors are alive today, compared to just 3 ... reported Tuesday. These individuals amount to 4 percent ... childhood cancer, according to the association,s annual progress report. ... treatment of cancer and details some of the challenges ...
(Date:9/16/2014)... for Radiation Oncology (ASTRO) has selected C.M. Charlie Ma, ... Oncology, and Director of Medical Physics at Fox ... The distinguished members selected to receive the Fellow of ... on Tuesday, September 16, at the ASTRO,s 56th Annual ... Fellows designation is a great honor and we are ...
Breaking Medicine News(10 mins):Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Some Benefits of Screening Elderly Women for Breast Cancer Questioned 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... A new UC Irvine study finds that lithium chloride, ... the development of inclusion body myositis, a skeletal muscle ... by scientists Frank LaFerla and Masashi Kitazawa, mice genetically ... six months after receiving daily doses of lithium chloride, ...
... Go,Healthcare, Inc. (OTC Bulletin Board: OGOH; ,OTG, ,the ... integrator,announced today that after more than four industry ... Value Added Reseller (,VAR,),business unit to Tampa, FL ... of the sale, in the amount of $4 ...
... to scenic attractions, COLUMBIA, S.C., March 18 ... Costa Rica for care now have a convenient ... farms, biological reserves,and other breathtaking scenery while awaiting ... division of Columbia, S.C.-based Companion,Global Healthcare Inc., has ...
... study appearing in the March 2008 issue of the ... natural family planning method developed by researchers from Georgetown ... women to family planning. More than half the women ... used family planning and on average, contraceptive use increased ...
... DALLAS, March 18 Phoenix Health Systems, a ... on the,business goals of healthcare organizations, announced today ... Management Services, Inc.,(TMSI) has awarded Phoenix Health Systems, ... TMSI performs considerable due diligence to,make certain the ...
... N.J., March 18 Barr,Pharmaceuticals, Inc. (NYSE: ... (LSE: PLVD), sent Notice to Deutsche Bank, acting ... Deposit Agreement (the "Deposit,Agreement") effective June 19, 2008 ... PLIVA will seek to delist from the London,Stock ...
Cached Medicine News:Health News:Lithium chloride slows onset of skeletal muscle disorder 2Health News:Lithium chloride slows onset of skeletal muscle disorder 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 2Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 3Health News:On The Go Healthcare Sells VAR Business to Wireless and Internet Space Development Leader FTS Group 4Health News:Companion Global Dental Clients Have New Reason to Smile in Costa Rica 2Health News:New choices bring wider range of women to family planning 2Health News:Texas Organization of Rural and Community Hospitals (TORCH) Awards Phoenix Health Systems Endorsed Vendor Status 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 2Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 3Health News:Barr's PLIVA Subsidiary to Terminate GDR Deposit Agreement and Delist From London Stock Exchange 4
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Concave inner surface to conform to the globe. Indications: Wide scleral bed. Outside diameter 32 mm....
Medicine Products: